AnatolyDritschiloMDFACR
Radiation Oncology • Washington, DCBreast Cancer, Head & Neck, Skin Cancer
Professor of Medicine, Georgetown University
Dr. Dritschilo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd Nw
Washington, DC 20007Phone+1 202-444-3320
Education & Training
Tufts Medical CenterResidency, Radiation Oncology, 1977 - 1977
Brigham and Women's Hospital/Joint Center for Radiation TherapyResidency, Radiation Oncology, 1974 - 1977
University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1973 - 1974
Rutgers New Jersey Medical SchoolClass of 1973
Certifications & Licensure
DC State Medical License 1979 - 2024
MD State Medical License 1980 - 2024
VA State Medical License 1997 - 2018- American Board of Radiology Therapeutic Radiology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies Start of enrollment: 2001 Mar 01
Publications & Presentations
PubMed
- 2 citationsCell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma.Satish Kumar Reddy Noonepalle, Maria Gracia-Hernandez, Nima Aghdam, Michael Berrigan, Hawa Coulibaly
Journal of Experimental & Clinical Cancer Research. 2024-09-14 - Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth.Mira Jung, Nicole Nicholas, Scott Grindrod, Anatoly Dritschilo
Plos One. 2024-01-01 - 4 citationsRadiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition.Satish Kumar R Noonepalle, Scott Grindrod, Nima Aghdam, Xintang Li, Maria Gracia-Hernandez
Molecular Cancer Therapeutics. 2023-12-01
Press Mentions
Shuttle Pharmaceuticals Holdings, Inc. Finalizes Agreements for Phase 2 Clinical Trial Enrollment: Press Release AnalysisOctober 30th, 2024- Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate UpdateMay 26th, 2023
- Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation CandidatesMarch 22nd, 2023
- Join now to see all
Grant Support
- Mechanisms Of Cellular Responses To Ionizing RadiationNational Cancer Institute1997–2006
- Cancer Center Support GrantNational Cancer Institute2005
- Georgetown University AP4 Center PLANNational Cancer Institute2004
- Radiosensitization Of Pancreatic Cancers Through RAF-1National Cancer Institute2002
- Molecular Studies Of Radiation Resistant Tumor CellsNational Cancer Institute1997–2001
- ATM Gene In Breast Cancer--Prospective Clinical TrialNational Cancer Institute1997–2001
- Molecular Studies Of Radiation Resistant Tumor CellsNational Cancer Institute1987–2000
- Oligonucleotide Manipulation--Tumor Cell RadioresistanceNational Cancer Institute1994
- Radiation Resistance And Adp-Ribose MetabolismNational Cancer Institute1992–1994
- Molecular Basis Of Tumor Resistance To Ionize RadiationNational Cancer Institute1990–1992
- Characterization Of Differential Gene Expression In Resistant CellsNational Cancer Institute1990–1992
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
